Disrupted glutamate-glutamine cycle in acute encephalopathy with biphasic seizures and late reduced diffusion

Jun-Ichi Takanashi1, Masashi Mizuguchi2, Masaru Terai3

  • 1Department of Pediatrics, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, 477-96 Owadashinden, Yachiyo-shi, 276-8524, Japan. jtaka44@hotmail.co.jp.

Neuroradiology
|August 24, 2015
PubMed

Insights

Magnetic resonance spectroscopy may aid early diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). Glutamate elevation occurs early, followed by glutamine elevation, indicating a disrupted glutamate-glutamine cycle.

Area of Science:

  • Pediatric Neurology
  • Neuroimaging
  • Biochemistry

Background:

  • Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a common pediatric encephalopathy in Japan.
  • Early diagnosis of AESD is challenging.
  • Excitotoxicity, involving glutamate and glutamine, is a suspected pathogenic mechanism.
Abstract

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
969
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K